BE680692A - - Google Patents
Info
- Publication number
- BE680692A BE680692A BE680692DA BE680692A BE 680692 A BE680692 A BE 680692A BE 680692D A BE680692D A BE 680692DA BE 680692 A BE680692 A BE 680692A
- Authority
- BE
- Belgium
- Prior art keywords
- amylase
- day
- therapeutic composition
- composition according
- acetyl
- Prior art date
Links
- 239000004382 Amylase Substances 0.000 claims description 37
- 102000013142 Amylases Human genes 0.000 claims description 37
- 108010065511 Amylases Proteins 0.000 claims description 37
- 235000019418 amylase Nutrition 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 23
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 21
- 239000000829 suppository Substances 0.000 claims description 15
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 230000001754 anti-pyretic effect Effects 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 239000002221 antipyretic Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 241001306288 Ophrys fuciflora Species 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000002497 edematous effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 25
- 239000003826 tablet Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 17
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 12
- 239000008298 dragée Substances 0.000 description 11
- 229960005489 paracetamol Drugs 0.000 description 11
- 239000007940 sugar coated tablet Substances 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 108090000317 Chymotrypsin Proteins 0.000 description 9
- 229960002376 chymotrypsin Drugs 0.000 description 9
- 230000008034 disappearance Effects 0.000 description 9
- 108010003272 Hyaluronate lyase Proteins 0.000 description 8
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 8
- 230000003501 anti-edematous effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229960002773 hyaluronidase Drugs 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 208000005141 Otitis Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000019258 ear infection Diseases 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000288140 Gruiformes Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 108010032809 mucopolysaccharidase Proteins 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 206010037833 rales Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 244000180278 Copernicia prunifera Species 0.000 description 2
- 235000010919 Copernicia prunifera Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 208000027499 body ache Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010048750 Axillary pain Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010053582 Bronchopneumopathy Diseases 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001315286 Damon Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010030094 Odynophagia Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- -1 acetyl para-aminophenol Chemical compound 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N p-hydroxyphenylamine Natural products NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR17557A FR4196M (pm) | 1965-05-19 | 1965-05-19 | |
| FR31188A FR4825M (pm) | 1965-09-13 | 1965-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE680692A true BE680692A (pm) | 1966-10-17 |
Family
ID=26163909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE680692D BE680692A (pm) | 1965-05-19 | 1966-05-06 |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE680692A (pm) |
-
1966
- 1966-05-06 BE BE680692D patent/BE680692A/fr not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5945106A (en) | Montoxic extract of Larrea tridentata and method of making the same | |
| JP4365107B2 (ja) | 医薬組成物 | |
| AU720132B2 (en) | Pharmaceutical compositions | |
| CA1328621C (fr) | Formes galeniques de beta-2-mimetiques pour administration par voie per- et sublinguale | |
| EP0945132A2 (en) | Ibuprofen composition | |
| JPH02502915A (ja) | 脂肪酸及びモノグリセリドの抗ウイルス及び抗菌活性 | |
| NO922232D0 (no) | Fysiologisk aktivt polypeptidholdig farmasoeytisk preparat | |
| JP6474114B2 (ja) | 睡眠障害の治療用のカノコソウ根抽出物とラベンダーオイルの組合わせ | |
| FR2577136A1 (fr) | Preparations pharmaceutiques a activite analgesique comportant des sels de diclofenac et de codeine, ainsi que leur fabrication et leur utilisation | |
| EP0578733A1 (fr) | Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme | |
| RU2391989C2 (ru) | Фармацевтическая гепатопротекторная композиция и способ лечения | |
| BE680692A (pm) | ||
| FR2464715A1 (fr) | Utilisation de derives de glycerylphosphoryle dans la therapie des dyslipemies, des hepatites et des etats pathologiques analogues et compositions pharmaceutiques pour cette therapie | |
| JPH11510168A (ja) | 呼吸障害を処理するための鎮痛剤及び抗ヒスタミン剤を含有する組成物及び方法 | |
| EP2919752A1 (fr) | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate | |
| CN102772434B (zh) | 一种治疗脑瘫药物或功能食品的应用及其制备方法 | |
| JP2005500995A (ja) | Ｂ型肝炎ウイルスにより起きる感染症の治療または予防のためのフィランタス属構成部分の使用 | |
| BE692681A (pm) | ||
| JP2938579B2 (ja) | 消化管壁保護剤 | |
| RU2244554C1 (ru) | Средство для лечения вирусного гепатита с | |
| WO2001037823A1 (en) | Substituted nitrobenzene derivatives as medicines and other useful uses thereof | |
| WO2022168169A1 (ja) | 抗ウイルス剤 | |
| WO2021260671A1 (fr) | Extrait d'un champignon de la famille des boletus fungi pour son utilisation notamment dans la prévention de la maladie covid 19 | |
| BE836383R (fr) | Pyridone n-substituee utile et procede general de preparation de pyridones | |
| RU2004128011A (ru) | Лекарственное средство и способ оздоровления человека и животных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: LABORATOIRE SOLAC S.A. Effective date: 19860506 |